2. MAPK/ERK Pathway Autophagy Anti-infection
  3. MEK Autophagy Mitophagy Influenza Virus
  4. U0126-EtOH

U0126 (U0126-EtOH) is a potent, non-ATP competitive and selective MEK1 and MEK2 inhibitor, with IC50s of 72 nM and 58 nM, respectively. U0126 is an autophagy and mitophagy inhibitor.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

CAS 番号 : 1173097-76-1

容量 価格（税別） 在庫状況 数量
>無料サンプル (0.1 - 0.2 mg)   今すぐ申し込む  
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 USD 41 在庫あり
Solution
10 mM * 1 mL in DMSO USD 41 在庫あり
Solid
5 mg $38 在庫あり
10 mg $60 在庫あり
20 mg $80 在庫あり
25 mg $86 在庫あり
50 mg $106 在庫あり
100 mg $132 在庫あり
200 mg $180 在庫あり
250 mg $210 在庫あり
500 mg $294 在庫あり
1 g   お問い合わせ  
5 g   お問い合わせ  

* アイテムを追加する前、数量をご選択ください

This product is a controlled substance and not for sale in your territory.

カスタマーレビュー

Based on 459 publication(s) in Google Scholar

Other Forms of U0126-EtOH:

U0126-EtOH 関連抗体

Top Publications Citing Use of Products

顧客検証

IP
Bio/Physico-chemical Assay
Cell Proliferation/Viability Assay
Cell Imaging/Staining
WB
RT-PCR
IF

    U0126-EtOH purchased from MedChemExpress. Usage Cited in: Nat Immunol. 2025 Oct;26(10):1673-1685.  [Abstract]

    U0126 (20 μM, 30 min) and Mirdametinib enhanced LDH release in rPFO-treated HeLa cells.

    U0126-EtOH purchased from MedChemExpress. Usage Cited in: Nat Immunol. 2025 Oct;26(10):1673-1685.  [Abstract]

    U0126 (20 μM, 30 min) and Mirdametinib enhanced rPFO-induced TGN remodeling and NLRP3 recruitment in HeLa NLRP3-GFP cells.

    U0126-EtOH purchased from MedChemExpress. Usage Cited in: Nat Immunol. 2025 Oct;26(10):1673-1685.  [Abstract]

    U0126 (20 μM, 30 min) and Mirdametinib enhanced rPFO-induced TGN remodeling and NLRP3 recruitment in HeLa NLRP3-GFP cells.

    U0126-EtOH purchased from MedChemExpress. Usage Cited in: Cancer Commun (Lond). 2024 Nov;44(11):1350-1373.  [Abstract]

    Ubiquitination assays in A549 cells showed that U0126 (2 μmol/L, 24 h) augments SET1A ubiquitination.

    U0126-EtOH purchased from MedChemExpress. Usage Cited in: Cancer Commun (Lond). 2024 Nov;44(11):1350-1373.  [Abstract]

    U0126 (1-20 μmol/L, 24 h) significantly reduced FGL1 levels in KRAS-mutant lung cancer cells H358.

    U0126-EtOH purchased from MedChemExpress. Usage Cited in: NPJ Biofilms Microbiomes. 2024 Jan 20;10(1):5.  [Abstract]

    Percentage cell proliferation of CT26 cells treated with MEK inhibitor U0126-EtOH (HY-12031; 25 µM), JNK inhibitor SP600125 (HY-12041; 25 µM), P38/MAPK inhibitor SB202190 (HY-10295; 20 µM), GSK3β inhibitor TWS119 (HY-10590; 20 µM), or AR-A014418 (HY-10512; 20 µM), and vehicle or Cori.ST1911. Cell OD was measured using the CCK8 method and normalised to cell proliferation of the control. Inhibitor treatment started 4 h before Cori.ST1911 treatment. Data are represented as mean ± SEM (n = 3 independent tests), analysed by one-way analysis of variance (ANOVA) with Bonferroni’s post-hoc test. n.s., no significance.

    U0126-EtOH purchased from MedChemExpress. Usage Cited in: Biochem Pharmacol. 2023 Apr:210:115489.  [Abstract]

    U0126 (20 uM; pretreat for 2 h) rescues the loss of UHRF1/DNMT1 expression and the increase of E-Cadherin expression that induced by Lenvatinib in Huh7 cells.

    U0126-EtOH purchased from MedChemExpress. Usage Cited in: Mol Cell Endocrinol. 2023 May 1:566-567:111891.  [Abstract]

    U0126 (10 uM; pre-treate for 1 h) attenuates IL-1-induced upregulation of COX-2 expression in KGN cells.

    U0126-EtOH purchased from MedChemExpress. Usage Cited in: Cancer Res. 2019 Sep 1;79(17):4466-4479.  [Abstract]

    Western blot and IHC analyses for p-ERK1/2 in lung tissues after vehicle or U0126 treatment.

    U0126-EtOH purchased from MedChemExpress. Usage Cited in: Am J Physiol Renal Physiol. 2019 Apr 1;316(4):F660-F673.  [Abstract]

    Western analysis of Vimentin, E-cadherin and Snail1 protein expression with or without the treatment of U0126.

    U0126-EtOH purchased from MedChemExpress. Usage Cited in: Am J Physiol Renal Physiol. 2019 Apr 1;316(4):F660-F673.  [Abstract]

    Western analysis of α-SMA, Collagen I and E-cadherin protein expression in the treatment of U0126 with different concentrations.

    U0126-EtOH purchased from MedChemExpress. Usage Cited in: Acta Biochim Biophys Sin (Shanghai). 2019 Apr 1;51(4):365-374.  [Abstract]

    MAPKs inhibitors suppress LPS-induced COX-2 expression and AKT1 phosphorylation. RAW264.7 cells are pretreated for 1 h with U0126, SB202190, SP600125 alone, or all the three inhibitors, respectively, and then exposed to 40 ng/ml LPS for 30 min or 12 h. The phosphorylated protein kinases and COX-2 expression are detected by western blot analysis using their corresponding antibodies.

    U0126-EtOH purchased from MedChemExpress. Usage Cited in: Blood. 2018 Jul 12;132(2):210-222.  [Abstract]

    Phosphorylation of p-ERK1/2 and p-Akt in MKs pretreated with 0.5 μM NVP-ADW742, 10 μM U0126 or 20 μM LY294002 followed by rhIGF-1 treatment for 15 minutes.

    U0126-EtOH purchased from MedChemExpress. Usage Cited in: Biomaterials. 2018 Sep;178:95-108.  [Abstract]

    U0126 effectively inhibits the phosphorylation of ERK, leading to the inhibition of IL-10 production.

    U0126-EtOH purchased from MedChemExpress. Usage Cited in: J Neuroinflammation. 2018 Jun 15;15(1):184.  [Abstract]

    Representative immunoblots of total lysates from BV2 cells treated with MPP+or/and U0126 (10 μM), SP600125 (SP, 10 μM) and SB203580 (SB, 10 μM) using the antibodies against DICER.

    U0126-EtOH purchased from MedChemExpress. Usage Cited in: Cancer Lett. 2018 Aug 28:430:201-214.  [Abstract]

    Inhibition of ERK suppresses N-cadherin expression. CD146WT or CD146KO MEFs are stimulated with or without TGF-β1 (10 ng/mL) for 24 h in the presence or absence of U0126 (2 μM). The expression and activation of ERK and the expression of E-cadherin and N-cadherin is assessed by immunoblotting.

    U0126-EtOH purchased from MedChemExpress. Usage Cited in: J Neuroinflammation. 2018 Oct 19;15(1):291.  [Abstract]

    Blocking the three MAPK signaling pathways through specific inhibitors (U0126; SB202190; and SP600125) significantly decrease the infection-induced neuroinflammatory response via real-time PCR analysis.

    U0126-EtOH purchased from MedChemExpress. Usage Cited in: J Neuroinflammation. 2018 Oct 19;15(1):291.  [Abstract]

    Blocking the three MAPK signaling pathways through specific inhibitors (U0126; SB202190; and SP600125) significantly decrease the infection-induced neuroinflammatory response via real-time PCR analysis.

    U0126-EtOH purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2018 Oct 3;9(10):1015.  [Abstract]

    Representative western blot images are showing the LC3, and the phosphorylated and total protein expression of Akt and ERK1/2 after treatment with H2O2 in the presence and absence of MK2206 (5 μM) and U0126 (25 μM).

    U0126-EtOH purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2018 Feb 15;9(3):269.  [Abstract]

    WB is used to detect the effect of EGF treatment on the expression of YAP with the inhibitors of EGFR or its downsream members.

    U0126-EtOH purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2018 Mar 15:42:152-163.  [Abstract]

    Cells are pretreated with SP600125 (20 μM), SB203580 (20 μM) or U0126 (20 μM) in presence or absence of KLA, then incubated with LPS (1 μg/mL) for certain time. Cell lysates are subjected to western blot.

    U0126-EtOH purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2018 Apr:100:417-425.  [Abstract]

    HaCaT cells are pre-incubated with Compound C (CC) (10 μM) and U0126 (10 μM), pharmacological inhibitors of AMPKα, ERK, respectively, for 1 h before treatment with DA8 and DA14 (DAs).

    U0126-EtOH purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2018 Dec:108:1294-1302.  [Abstract]

    The protein levels of IL-1β and TNF-α are sharply downregulated by the addition of inhibitors SB203580, SP600125, and U0126.

    U0126-EtOH purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2018 Dec:108:1294-1302.  [Abstract]

    The protein level of MMP-9 is downregulated by inhibitors SB203580, SP600125, and U0126.

    U0126-EtOH purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2018 Dec:108:1294-1302.  [Abstract]

    As for both 0 g and 3 g groups, the p-ERK1/2/ERK1/2 is notably reduced by inhibitors SB203580, SP600125, and U0126.

    U0126-EtOH purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2018 Dec:108:1294-1302.  [Abstract]

    As for both 0 g and 3 g groups, the p-p38&p38 is downregulated by inhibitors SB203580, SP600125, and U0126.

    U0126-EtOH purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2018 Dec:108:1294-1302.  [Abstract]

    As for both 0 g and 3 g groups, the p-JNK1&JNK1 is downregulated by inhibitors SB203580, SP600125, and U0126.

    U0126-EtOH purchased from MedChemExpress. Usage Cited in: Front Immunol. 2018 Dec 7:9:2854.  [Abstract]

    Neutrophils are pretreated with inhibitor of p38 MAPK (SB203580) and ERK1/2 (U0126), and the cells are then incubated with either SS2 ZY05719 or PMA for 3 h. Immunofluorescence is performed.

    U0126-EtOH purchased from MedChemExpress. Usage Cited in: Reprod Biol Endocrinol. 2018 May 31;16(1):55.  [Abstract]

    Western blot analysis of claudin 5, occludin and ZO-1 in TM4 cells, cells are treated with 100 nM Leptin or pre-treated with different inhibitors following a 100 nM Leptin treatment.

    U0126-EtOH purchased from MedChemExpress. Usage Cited in: Mol Med Rep. 2018 Jun;17(6):7595-7602.  [Abstract]

    Representative images show the expression levels of α SMA, calponin and osteopontin (OPN) protein.

    U0126-EtOH purchased from MedChemExpress. Usage Cited in: J Cell Biochem. 2019 Feb;120(2):1979-1989.  [Abstract]

    Western blot shows the expression of p-ERK and MMP13 with the treatment of U0126 and CCL17.

    U0126-EtOH purchased from MedChemExpress. Usage Cited in: Cell Physiol Biochem. 2018;50(4):1522-1534.  [Abstract]

    Western analysis of effect of U0126 on Nell-1-induced changes in p-ERK, Runx2, OPG and Col-I protein expression in MC3T3-E1 preosteoblasts on Ti surfaces.

    U0126-EtOH purchased from MedChemExpress. Usage Cited in: Cancer Lett. 2017 May 1:393:22-32.  [Abstract]

    Effects of p38 MAPK inhibitor (SB203580), ERK inhibitor (U0126), JNK inhibitor (SP600125), caspase inhibitor (Z-VAD-FMK) and NAC on SGC-7901 and MGC-803 treated with DOX/VCPA combination treatment. VCPA pretreatment strategy is the same as above. SB203580 (20 μM), U0126 (10 μM), SP600125 (20 μM), Z-VAD-FMK (10 μM) and NAC (5 mM) are treated 2 h before DOX (2 μg/mL) added into the culture, respectively. MAPK pathway protein levels are determined.

    U0126-EtOH purchased from MedChemExpress. Usage Cited in: Free Radic Biol Med. 2017 Nov:112:49-59.  [Abstract]

    Cells are pre-treated with ERK (U1026) and p38 (SB203580) inhibitors, followed by GL-V9 treatment for 24 h. Western blot is performed to analyze NAG-1 expression.

    U0126-EtOH purchased from MedChemExpress. Usage Cited in: Cell Signal. 2017 Apr:32:48-58.  [Abstract]

    Western blotting showing the hepaCAMexpression and the phosphorylation level of STAT3, ERK and AKT in cells treated with IL-6 (20 ng/mL) for 24 h with or without the pretreatment of two respective inhibitors, Stattic (10 μM) and U0126 (5 μM).

    U0126-EtOH purchased from MedChemExpress. Usage Cited in: Cell Cycle. 2017 Apr 3;16(7):714-722.  [Abstract]

    Proliferation of OPCs by AST induced calcium signaling and phosphorylated ERK1/2. p-ERK levels decreased after Cx47 siRNA treatment and U0126-mediated ERK1/2 inhibition. The results of Western blotting show that U0126 causes a marked decrease in ERK1/2 phosphorylation

    U0126-EtOH purchased from MedChemExpress. Usage Cited in: Oxid Med Cell Longev. 2017:2017:6175841.  [Abstract]

    Involvements of MAPK signaling pathway in CPS-induced apoptosis in ALI cultures of sheep bronchial epithelial cells. Cells are pretreated with U0126 (an ERK1/2 inhibitor, 10 μM) for 1 h, followed by exposure to CPS (100 ng/mL) or MO (MOI = 30) for 48 h. Cell lysates are subjected to Western blotting analysis using indicated antibodies.

    U0126-EtOH purchased from MedChemExpress. Usage Cited in: Oncotarget. 2017 May 16;8(20):33807-33826.  [Abstract]

    U0126 inhibits ERK1/2 activation in the kidney of hyperuricemic rats. Rat model of HN is established by feeding with adenine and potassium oxonate daily. In some rats, U0126 are simultaneously administrated intraperitoneally. After 28 days, the kidneys are taken for immunoblot analysis of p-ERK1/2, ERK1/2 or GAPDH.

    U0126-EtOH purchased from MedChemExpress. Usage Cited in: Oxid Med Cell Longev. 2017:2017:7426458.  [Abstract]

    Representative immunoblot analysis of p53, p16, p21, and retinoblastoma protein (Rb) in NP cells.

    U0126-EtOH purchased from MedChemExpress. Usage Cited in: Oncotarget. 2017 May 30;8(47):82027-82036.  [Abstract]

    U0126 and MEK162 block ERK activation (p-ERK1/2) in CZ415-treated U2OS cells.

    U0126-EtOH purchased from MedChemExpress. Usage Cited in: J Mol Cell Cardiol. 2015 Dec;89(Pt B):268-79.  [Abstract]

    Dose response of MAPK and Akt inhibitors on cardiac fibroblast-derived exosomes (Exo)-induced activation of MAPKs and Akt. Neonatal rat cardiomyocytes are treated with or without Exo (50 μg/mL), U0126, SP600125, MK-2206, and SB023580 for 20 min and subjected to Western blot analysis. The results are from 4 separate experiments.

    U0126-EtOH purchased from MedChemExpress. Usage Cited in: ACS Chem Neurosci. 2015 Jan 21;6(1):130-7.  [Abstract]

    U0126 protects PC12 cells against H2O2-induced cell death. Western blot of ERK phosphorylation demonstrates that the MEK inhibitors U0126, GSK1120212 and Pimasertib are effective in blocking ERK phosphorylation under complete media, while U0124 results in slight ERK inhibition compared to DMSO control. Serum starvation results in lack of ERK phosphorylation in all conditions.

    MEK アイソフォーム固有の製品をすべて表示:

    すべてのアイソフォームを表示
    MEK1 MEK2 MEK5 MEK MAP2K4/MEK4 MAP2K7/MEK7

    • 生物活性

    • 純度とドキュメンテーション

    • 参考文献

    • カスタマーレビュー

    製品説明

    U0126 (U0126-EtOH) is a potent, non-ATP competitive and selective MEK1 and MEK2 inhibitor, with IC50s of 72 nM and 58 nM, respectively. U0126 is an autophagy and mitophagy inhibitor[1][2][3][4].

    IC50 & Target[1]

    MEK2

    60 nM (IC50)

    MEK1

    70 nM (IC50)

    体外実験

    Treatment with U0126-EtOH (U0126) efficiently reduces progeny virus titers of all tested strains in A549 cells. While nM concentrations of U0126-EtOH are efficient to reduce H1N1v and H5N1 (MB1), μM concentrations of U0126-EtOH are required to reduce the virus titer of H5N1 (GSB) and H7N7. The EC50 values for U0126-EtOH against H1N1v are 1.2±0.4 μM in A549 cells and 74.7±1.0 μM in MDCKII cells[2].
    Rat hepatocarcinoma cells (FAO) stimulated by fetal calf serum (FCS) exhibits a significant proportion in S phase (32.62%) whereas U0126-EtOH (U0126) strongly decreases the proportion of cells in S phase (9.92%) and increases the proportion of cells in G0-G1 phase and to a lesser extent in G2/M[3].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    U0126-EtOH 関連抗体

    Cell Viability Assay[2]

    Cell Line: A549 and MDCK II cells.
    Concentration: 0.001-1000 μM.
    Incubation Time: 48 h.
    Result: The EC50 values for U0126 against H1N1v were 1.2 ± 0.4 μM in A549 cells and 74.7 ± 1.0 μM in MDCKII cells
    体内実験

    Mice are treated daily with U0126-EtOH (U0126; i.p., 10.5 mg/kg). In control experiment, tumor sizes are constant or slightly increase all over the kinetic. At the opposite, in all U0126-EtOH experiments, engraftment and early tumor growth are significantly decreased. Furthermore, a 60-70% reduction in the volume of tumors treated with U0126-EtOH is obtained 9 days after injection and thereafter[3].
    Rats are subjected to 120 minutes transient middle cerebral artery occlusion (tMCAO) and thereafter treated with the U0126-EtOH (U0126; i.p., 30 mg/kg) at 0 and 24 hours of reperfusion. After treatment with U0126-EtOH, the vasoconstriction to S6c is markedly reduced[4].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: Athymic female nude mice (SWISS, nu/nu)[3].
    Dosage: 10.5 mg/kg.
    Administration: Intraperitoneal injection daily.
    Result: Inhibited tumor growth.
    Animal Model: Twelve-week-old female Wistar rats (250 to 265 g)[4].
    Dosage: 30 mg/kg.
    Administration: Intraperitoneally.
    Result: The vasoconstriction to S6c is markedly reduced.
    分子量

    426.56

    分子式

    C20H22N6OS2
    CAS 番号
    Appearance

    Solid

    Color

    White to light brown

    SMILES

    NC1=CC=CC=C1S/C(N)=C(/C(C#N)=C(SC2=C(C=CC=C2)N)\N)C#N.CCO
    輸送条件

    Room temperature in continental US; may vary elsewhere.
    保管条件
    Powder -20°C 3 years
      4°C 2 years
    In solvent -80°C 6 months
      -20°C 1 month
    溶剤 & 溶解度
    体外: 

    DMSO : 50 mg/mL (117.22 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    Ethanol : 2.38 mg/mL (5.58 mM; Need ultrasonic)

    H2O : < 0.1 mg/mL (insoluble)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 2.3443 mL 11.7217 mL 23.4434 mL
    5 mM 0.4689 mL 2.3443 mL 4.6887 mL
    10 mM 0.2344 mL 1.1722 mL 2.3443 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    一般には略語で表示されます：C1V1 = C2V2

    濃度 （開始）

    C1

    ×
    体積 （開始）

    V1

    =
    濃度 （終了）

    C2

    ×
    体積 （終了）

    V2

    体内:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.08 mg/mL (4.88 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 2.08 mg/mL (4.88 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.

    For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  0.5% CMC-Na/saline water

      Solubility: 5 mg/mL (11.72 mM); Suspended solution; Need ultrasonic

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    純度とドキュメンテーション

    純度: 99.41%

    COA (246 KB) HNMR (269 KB) LCMS (265 KB) Elemental Analysis Report (105 KB)

    取扱説明書 (2659 KB)
    参考文献

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    Ethanol / DMSO 1 mM 2.3443 mL 11.7217 mL 23.4434 mL 58.6084 mL
    5 mM 0.4689 mL 2.3443 mL 4.6887 mL 11.7217 mL
    DMSO 10 mM 0.2344 mL 1.1722 mL 2.3443 mL 5.8608 mL
    15 mM 0.1563 mL 0.7814 mL 1.5629 mL 3.9072 mL
    20 mM 0.1172 mL 0.5861 mL 1.1722 mL 2.9304 mL
    25 mM 0.0938 mL 0.4689 mL 0.9377 mL 2.3443 mL
    30 mM 0.0781 mL 0.3907 mL 0.7814 mL 1.9536 mL
    40 mM 0.0586 mL 0.2930 mL 0.5861 mL 1.4652 mL
    50 mM 0.0469 mL 0.2344 mL 0.4689 mL 1.1722 mL
    60 mM 0.0391 mL 0.1954 mL 0.3907 mL 0.9768 mL
    80 mM 0.0293 mL 0.1465 mL 0.2930 mL 0.7326 mL
    100 mM 0.0234 mL 0.1172 mL 0.2344 mL 0.5861 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    U0126-EtOH Related Classifications

    • Molarity Calculator

    • Dilution Calculator

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    質量   濃度   体積   分子量 *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    一般には略語で表示されます：C1V1 = C2V2

    濃度 （開始） × 体積 （開始） = 濃度 （終了） × 体積 （終了）
    × = ×
    C1   V1   C2   V2
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    U0126-EtOH1173097-76-1MEKAutophagyMitophagyInfluenza VirusMitogen-activated protein kinase kinaseMAPKKMAP2KMitochondrial Autophagynon-ATPcompetitiveprogenyvirusInhibitorinhibitorinhibit

    最近チェックした製品:

    オンラインお問い合わせ

    Your information is safe with us. * Required Fields.

    製品名

    		  

    カスタマ需要量 *

    お名前 *

    		 

    タイトル

    メールアドレス *

    		 

    電話番号 *

    デパートメント

    		 

    組纖名 *

    市区町村

    都道府県

    国或いは地域 *

    		      

    必ず会社名を記載ください。個人への返信は行いません。

    備考

    バルクお問い合わせ

    Inquiry Information

    製品名:
    U0126-EtOH
    製品番号:
    HY-12031
    数量:
    MCE 日本正規代理店:

    カスタマーレビュー

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    製品名

    		  

    Lot #

    お名前 *

    		 

    メールアドレス *

    電話番号 *

    		 

    部門 *

    組纖名 *

    		 

    国或いは地域 *

    備考

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.